We estimate that the global insomnia therapeutics market was worth $918m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 4.9% to reach $1,343m by 2018. This steady growth is primarily attributed to the expected launch of pipeline products in 2014 (such as Intermezzo, tasimelteon and MK-4305 in the G7 countries, the launch of SEP-190 (eszopiclone) in Japan and the launch of ramelteon in Europe). Increasing awareness and treatment seeking rates for insomnia are expected to further contribute to the growth of the market. The impact of the patent expiry of Lunesta (eszopiclone) in 2014, an approved drug for chronic insomnia in the US, is expected to be minimal due to the launch of pipeline drugs in the same year.

Current Treatment Options are Moderately Successful in Meeting Market Demand

The global insomnia therapeutics market currently has non-benzodiazepines (zolpidem, zaleplon and Lunesta), selective melatonin receptors (ramelteon), benzodiazepines (triazolam, temezapam and estazolam), Over The Counter (OTC) (vitamin and melatonin supplements) and off label drugs (trazodone, mitrazepine, amytriptyline) all of which have moderate levels of safety and efficacy. Lunesta is the only approved medication for chronic insomnia. Insomnia is prevalent in all ages of the population but the currently marketed drugs are not been approved for all age groups. The insomnia therapeutics market is therefore moderately successful in meeting the market demand.

Pipeline Candidates are Expected to Intensify the Future Competition

The developmental pipeline for insomnia is strong with 20 molecules in various Phases of development. The pipeline mainly includes Gaba-AminoButrytic Acid receptors (GABAA), -AminoButrytic Acid- Benzodiazepine binding sites (GABA-BZ), receptor antagonists, selective melatonin receptor antagonists, orexin receptor antagonists, histamine and dopamine receptor agonists, low dose formulation of zolpidem, experimental formulation of zaleplon and others. The developmental pipeline for insomnia has six First In Class (FIC) molecules, one molecule in Phase III and five in Phase II. MK-4305 in Phase III has the potential to compete with the currently marketed drugs. The effect of patent expiries and the presence of generics in the market are expected to be neutralized by the launch of the late stage pipeline products.

Current Treatment Options Leave a High Level of Unmet Need

The current insomnia therapeutics market has nine approved products for the treatment of insomnia. Eight of the approved drugs are for the treatment of transient insomnia while only one drug has been approved for chronic insomnia. There is a need for drugs that can be used for chronic insomnia. The available pharmacological treatments for insomnia have moderate safety and efficacy profiles. Physicians and patients alike prefer behavioral therapies to currently available medications due to the adverse effects (abuse potential) associated with them. Hence, there is a high unmet need for medications with better safety and efficacy profiles.

Report Overview

This report is an essential source of information and analysis on the global insomnia market. The report identifies the key trends shaping and driving the global insomnia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global insomnia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.

Scope

The report provides information on the key drivers and challenges of the insomnia market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) insomnia market revenues data from 2005 to 2010 forecast to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes of GABAA and GABA-BZ receptor antagonists, selective melatonin receptor antagonists, orexin receptor antagonists, histamine and dopamine receptor agonists, low dose formulation of zolpidem, experimental formulation of zaleplon and others.
- Analysis of the current and future competition in the global insomnia market. Key market players covered are Merck & Co, Eisai, Vanda, Transcept, and Takeda Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the insomnia therapeutics market.
- Analysis of key recent licensing and partnership agreements in the insomnia market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global insomnia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global insomnia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global insomnia market landscape? Identify, understand and capitalize.

Click for Report details:Insomnia Therapeutics - Pipeline Assessment and Market Forecasts to 2018